

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 January 2022 (20.01.2022)



(10) International Publication Number
WO 2022/016120 A1

(51) International Patent Classification:

A61K 31/198 (2006.01) A61K 9/00 (2006.01)
A61K 49/00 (2006.01)

(21) International Application Number:

PCT/US2021/042097

(22) International Filing Date:

16 July 2021 (16.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/053,228 17 July 2020 (17.07.2020) US

(71) Applicant: **ASHVATTHA THERAPEUTICS, INC.**
[US/US]; 1235 Radio Road, Suite 200, Redwood City, CA
94065 (US).

(72) Inventors: **CLELAND, Jeffrey L.**; 1235 Radio Road,
Suite 200, Redwood City, CA 94065 (US). **RANGARA-
MANUJAM, Kannan**; Wilmer Eye Institute, The Johns
Hopkins University, Room 6019, Smith Building, 400 N.
Broadway, Baltimore, MD 21231 (US). **KANNAN, Su-
jatha**; 1235 Radio Road, Suite 200, Redwood City, CA
94065 (US). **SHARMA, Rishi**; 1235 Radio Road, Suite
200, Redwood City, CA 94065 (US). **APPIANILA ROSA,
Santiago**; 1235 Radio Road, Suite 200, Redwood City, CA
94065 (US).

(74) Agent: **BOWLER, Joseph M.** et al.; Wolf, Greenfield &
Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,


HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY



(57) Abstract: In some aspects, the disclosure provides methods of treating or preventing one or more symptoms of a kidney injury, disease or disorder in a subject in need thereof. In some embodiments, the method comprises administering to the subject a dendrimer complexed, covalently conjugated, or intra-molecularly dispersed or encapsulated with one or more therapeutic or prophylactic agents, in an amount effective to treat, alleviate or prevent one or more symptoms of a kidney injury, disease or disorder. In some embodiments, the dendrimer is a generation 4, 5, 6, 7, or 8 poly(amidoamine) (PAMAM) dendrimers, and the therapeutic agents are one or more anti-inflammatory agents and/or PPAR- δ agonists.

WO 2022/016120 A1